Connect Biopharma Holdings (CNTB) Exchange Rate Effect (2024 - 2026)
Connect Biopharma Holdings' (CNTB) quarterly Exchange Rate Effect came in at $45000.0 in Q2 2026, down 79.91% year-over-year from $224000.0 in Q2 2025, and down 37.5% quarter-over-quarter from $72000.0 in Q1 2026.
Powered by 
Analysis
Connect Biopharma Holdings (CNTB) Exchange Rate Effect (2024 - 2026) Analysis & Trends
Connect Biopharma Holdings has disclosed Exchange Rate Effect across 3 years of filings, most recently posting $45000.0 for Q2 2026.
- In Q2 2026, Exchange Rate Effect fell 79.91% year-over-year to $45000.0; the TTM figure through Jun 2026 stood at $226000.0 (up 227.68% YoY), while the FY2025 annual figure was $408000.0, up 168.57% from the prior year.
- Exchange Rate Effect came in at $45000.0 for Q2 2026 at Connect Biopharma Holdings, down from $72000.0 in the prior quarter.
- In the past five years, Exchange Rate Effect ranged from a high of $507000.0 in Q3 2024 to a low of -$983000.0 in Q4 2024.
- Average Exchange Rate Effect over 3 years is -$7000.0, with a median of $65000.0 recorded in 2025.
- The largest YoY upside for Exchange Rate Effect was 133.94% in 2025 against a maximum downside of 88.56% in 2025.
- Over 3 years, Exchange Rate Effect stood at -$983000.0 in 2024, then soared by 105.19% to $51000.0 in 2025, then decreased by 11.76% to $45000.0 in 2026.
- Per Business Quant data, the three most recent Exchange Rate Effect figures were $45000.0 in Q2 2026, $72000.0 in Q1 2026, and $51000.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -19.00 Mn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | -3.70 Mn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | -300,000.00 |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -2.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | -2.45 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | -3.40 Mn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 315,000.00 |
| 10 | Connect Biopharma Holdings | 129.86 Mn | 129.86 Mn | - | 45,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 45,000.00 |
| Mar 31, 2026 | 72,000.00 |
| Dec 31, 2025 | 51,000.00 |
| Sep 30, 2025 | 58,000.00 |
| Jun 30, 2025 | 224,000.00 |
| Mar 31, 2025 | 75,000.00 |
| Dec 31, 2024 | -983,000.00 |
| Sep 30, 2024 | 507,000.00 |
| Jun 30, 2024 | 102,000.00 |
| Mar 31, 2024 | -221,000.00 |